Company: KROS
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001664710-25-000070
Chunk: 224

Company: Keros Therapeutics, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Item 1
Chunk 224
---
 $(2.46)Net income (loss) per share of common stock — diluted$(0.76)$(1.25)$2.86 $(2.46)

See notes to condensed consolidated financial statements. 

6

KEROS THERAPEUTICS, INC.

Condensed Consolidated Statements of Stockholders’ Equity

(In thousands, except share and per share data) 

(Unaudited)

COMMON STOCK$0.0001 PAR VALUEADDITIONALPAID-INCAPITALACCUMULATEDDEFICITTOTAL STOCKHOLDERS’  EQUITY SHARESAMOUNTAs of December 31, 202440,554,705 $4 $1,140,328 $(568,779)$571,553 Exercise of common stock options7,342 — 4 — 4 Stock-based compensation— — 8,863 — 8,863 Net income (loss)— — — 148,451 148,451 As of March 31, 202540,562,047 $4 $1,149,195 $(420,328)$728,871 Exercise of common stock options53,367 17 17 Stock-based compensation8,542 8,542 Net income (loss)(30,696)(30,696)As of June 30, 202540,615,414 $4 $1,157,754 $(451,024)$706,734 COMMON STOCK $0.0001 PAR VALUEADDITIONALPAID-INCAPITALACCUMULATEDDEFICITTOTAL STOCKHOLDERS’  EQUITY SHARESAMOUNTAs of December 31, 202331,841,084 $3 $713,636 $(381,426)$332,213 Issuance of common stock, net of underwriting discounts, commissions, and offering costs of $9,9434,025,000 — 151,057 — 151,057 Exercise of common stock options201,702 — 5,721 — 5,721 Stock-based compensation— — 8,070 — 8,070 Net income (loss)— — — (43,114)(43,114)As of March 31, 202436,067,786 $3 $878,484 $(424,540)$453,947 Issuance of common stock